About the Corporate Council
The ACAAI Corporate Council offers companies exposure to nearly 6,000 allergists and immunologists, including more than 3,000 who are board-certified by the ABAI. Participation in the Corporate Council also provides valuable access to the ACAAI Board of Regents and other key opinion leaders.
The Corporate Council is comprised of senior executives from pharmaceutical, medical device and other companies involved in the field of allergy and immunology. Two representatives from each participating company will hold seats on the Corporate Council and will be invited to the annual Corporate Council roundtable meeting.
The Council’s goal is to address critical issues in allergy and immunology, find solutions to pressing challenges, share knowledge of best practices and advise members on upcoming initiatives. By pooling resources and expertise, Corporate Council members and the ACAAI leadership can engage in joint problem-solving and explore collaborative opportunities to improve patient care and advance the mission of ACAAI.
To learn more about becoming a member of the ACAAI Corporate Council, please contact:
Director of Corporate Relations
American College of Allergy, Asthma & Immunology
2018 Corporate Council Partners
Aimmune Therapeutics, Inc.
8000 Marina Blvd. Suite 200
Brisbane, CA 94005-1884
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials in ages 4-55. AR101 is an oral biologic drug product with a characterized peanut protein profile for use in oral immunotherapy (OIT) in subjects with peanut allergy. For more information, please see www.aimmune.com.
1700 Royston Lane
Round Rock, Texas 78664
As the World Leader in Allergy Immunotherapy (AIT), the only treatment that treats the underlying cause of allergic disease, ALK is devoted to improving the quality of life for people with allergies by offering more convenient methods of administration, and thereby expanding the overall use of AIT to more patients. We are committed to broadening our presence in allergy care and will continue to innovate, develop, and market new solutions beyond AIT, that bring us closer to allergic patients. Our goal is to build an effective future growth platform to engage with allergic patients and connect them will Allergy Specialists earlier in the disease progression.
1800 Concord Pike
Wilmington, DE 19850
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com.
One Boston Scientific Way
Marlborough, MA 01752
Boston Scientific is committed to helping advance the diagnosis and treatment of pulmonary diseases by focusing on the development of less invasive devices and procedures. We have developed the first device to treat adult patients with severe asthma. Bronchial Thermoplasty (BT) delivered by the Alair™ System is a safe outpatient procedure clinically proven to provide long-lasting reduction in exacerbations. 79% of patients treated with BT had a significant improvement in their asthma-related quality of life.
1 DNA Way
5151 McCrimmon Parkway
Morrisville, NC 27560
Circassia is a specialty biopharmaceutical company focused on allergy and respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians, and we have a broad pipeline of allergy, asthma and COPD treatments in development.
1 DNA Way
South San Francisco, CA 94080
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
111 Virginia Street, Suite 300
Richmond, VA 23219
Kaléo is a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions.